GRIPOCITRON FITО

INSTRUCTIONS FOR MEDICAL USE OF THE MEDICINAL PRODUCT GRIPOCYTRON FITO

Composition:

Active substance: 1 tablet contains 12.5 mg or 25 mg of chlorophyllipt extract, thick (10.76:1) (extractant ethanol 93%);

Excipients: sugar, ascorbic acid, calcium stearate.

Pharmaceutical form. Tablets.

Main physicochemical properties: tablets from light green to green in color with specks, flat cylindrical, with a score line and bevel, with a characteristic odor.

Pharmacotherapeutic group. Preparations used for throat diseases. Antiseptics. ATC code R02A A20.

Pharmacological properties.

Pharmacodynamics.

Chlorophyllipt is a mixture of chlorophylls derived from eucalyptus leaves. The drug exerts antibacterial (bacteriostatic and bactericidal) effects against staphylococci, as well as antiseptic and anti-inflammatory actions.

Pharmacokinetics.

Not studied.

Clinical characteristics.

Indications. Upper respiratory tract diseases (tonsillitis, pharyngitis, laryngitis), as well as aphthous and ulcerative stomatitis.

Contraindications. Hypersensitivity to chlorophyllipt or to other components of the drug.

Interaction with other medicinal products and other forms of interaction. Enhances the action of antiseptic agents.

Special precautions for use

Prior to starting use, consult a physician.

After the first application, a pause of 6–8 hours should be observed. Course treatment with the drug may be continued only after confirming the absence of allergic reactions to the dense chlorophyllipt extract (possible swelling of the lips, nasal mucosa, pharynx, and other allergic reactions). If any of the above symptoms occur, discontinue use of the drug and consult a physician.

If a patient has known intolerance to certain sugars, consult a physician before taking this medicinal product.

Use during pregnancy or breastfeeding. The efficacy and safety of the drug during pregnancy or breastfeeding have not been studied; therefore, the drug should not be used in these patient groups.

Ability to affect reaction rate while driving or operating machinery. Not studied.

Method of administration and dosage.

For adults, tablets of 12.5 mg or 25 mg should be prescribed depending on the severity of the pathological process. The tablet should not be swallowed or chewed, but held in the mouth until completely dissolved. The daily dose for adults is 25 mg taken 5 times per day. Frequency of administration: 1 tablet (12.5 mg or 25 mg) every 4–5 hours. Treatment duration: 7 days.

Children. There is no experience with the use of the drug in children.

Overdose. May result in an intensification of adverse reactions.

Adverse reactions.

Immune system side effects: allergic reactions, including rash, itching, angioedema, hyperemia.

Gastrointestinal side effects: irritation of the oral mucosa, nausea, vomiting.

Nervous system side effects: headache, dizziness.

Shelf life. 3 years.

Storage conditions. Store at a temperature not exceeding 25 °C in the original packaging.

Keep out of reach of children.

Packaging.

Tablets No. 20, No. 10x2 in blisters, in a carton.

Availability. Over-the-counter (without prescription).

Manufacturer.

Limited Liability Company "Research Plant "GNCLS".

Limited Liability Company "Pharmaceutical Company "Zdorovya".

Manufacturer's location and address of business activity.

8 Vorobiova Street, Kharkiv, Kharkiv region, 61057, Ukraine.

(Limited Liability Company "Research Plant "GNCLS")

22 Shevchenka Street, Kharkiv, Kharkiv region, 61013, Ukraine.

(Limited Liability Company "Pharmaceutical Company "Zdorovya")